Amarantus Biosciences (AMBS) Targets Apoptosis to Fight Parkinson’s and Cardiac Ischemia

August 23, 2011

Amarantus Biosciences Inc. (AMBS) is a development-stage biotechnology company, similar to companies like Zalicus Inc. (Nasdaq: ZLCS) and Exelixis Inc. (Nasdaq: EXEL), that is pioneering the study of how to prevent apoptosis or cell death. From its inventory of 88 proprietary cell lines, the company is developing a therapeutic protein called MANF to treat Parkinson’s Disease, cardiac ischemia and a wide range of other diseases and conditions.

Key Highlights

• Leader in Apoptosis Research. Amarantus Biosciences is a leader in the study of apoptosis, which is a natural process of programmed cell death that could be the culprit behind many diseases.
• Apoptosis’ Role in Parkinson’s Disease. Several studies have shown that apoptosis may play a critical role in Parkinson’s Disease and a range of other diseases and conditions.
• Antiapoptotic Potential in Cardiac Ischemia. Many studies have also suggested that preventing cell apoptosis may also be used to treat cardiac ischemia.

Note: There are several YouTube on Apoptosis/cell death; in several languages.